<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198086">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511992</url>
  </required_header>
  <id_info>
    <org_study_id>2674</org_study_id>
    <nct_id>NCT00511992</nct_id>
  </id_info>
  <brief_title>Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer</brief_title>
  <official_title>PHASE II STUDY OF PACLITAXEL (TAXOL), INTRAPERITONEAL CISPLATIN AND IV AVASTIN FOLLOWED BY AVASTIN CONSOLIDATION FOR ADVANCED OVARIAN AND PERITONEAL CARCINOMA OR FALLOPIAN TUBE CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with
      intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete
      6 cycles of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian cancer is the leading cause of death from gynecologic cancer in the United States.
      The high death rate stems from late presentation and tumor that has spread beyond the ovary
      at the time of diagnoses.

      Ovarian cancer typically spreads throughout the peritoneal cavity. Three randomized clinical
      trial have recently demonstrated the superiority of intraperitoneal(IP) over intravenous
      platinum based chemotherapy in optimally debulked advance ovarian cancer. The success of
      Bevacizumab in metastatic colorectal cancer has led to trials evaluating its' efficacy in
      advanced ovarian cancer. Based on the mechanism of action of Bevacizumab, there may be
      benefit of extended therapy with this agent.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe toxicities associated with intraperitoneal cisplatin with intravenous paclitaxel and Avastin.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Advanced Ovarian Carcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Ovarian Carcinosarcoma</condition>
  <arm_group>
    <arm_group_label>Avastin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Initial Treatment:
Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles, Cisplatin 75mg/m2 IP Day 2 every 21 days x 6 cycles, Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)
Consolidation Treatment:
Avastin 15mg/kg IV every 21 days x 12 cycles</description>
    <arm_group_label>Avastin</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stage II and III epithelial ovarian carcinoma, primary peritoneal
             carcinoma, or ovarian carcinosarcoma.

          -  Adequate bone marrow, renal, and hepatic function

          -  Patients must be entered no more than twelve weeks postoperatively

        Exclusion Criteria:

          -  Patients with epithelial ovarian carcinoma of low malignant potential (borderline
             carcinomas).

          -  Stage IV or suboptimally debulked disease following primary cytoreductive surgery

          -  Patients who have received prior radiotherapy or chemotherapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Scott McMeekin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 29, 2015</lastchanged_date>
  <firstreceived_date>August 3, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Gynecologic Cancer</keyword>
  <keyword>Ovarian Carcinoma</keyword>
  <keyword>Peritoneal Carcinoma</keyword>
  <keyword>IP chemotherapy</keyword>
  <keyword>Intraperitoneal</keyword>
  <keyword>Avastin</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
